JACOBIO-B (01167) announced that the company's board of directors has been further notified by members of persons acting in concert that, based on their firm confidence in the company's future development prospects, they have collectively purchased 11,058,650 shares of the company from July 16, 2025 to the date of this announcement, involving a total consideration of approximately HK$96.34 million.

As of the announcement date, the persons acting in concert collectively hold 200 million shares of the company, representing approximately 25.28% of the company's total issued shares. The aforementioned members of persons acting in concert expressed full confidence in the company's overall development prospects, growth potential, and the long-term investment value of its shares. Subject to compliance with applicable laws and regulatory requirements, they do not rule out the possibility of further increasing their holdings in the company's shares at appropriate times.

From July 15, 2025 to the announcement date, the company has cumulatively repurchased 326,400 shares, with a total consideration paid of HK$2.67 million. The company will continue to monitor market conditions and may further exercise the shareholder authorization for share repurchases based on market circumstances.

The announcement stated that the company's current business operations are in good condition, with smooth research and development progress of core product pipelines (including but not limited to Pan-KRAS inhibitors), and the data is encouraging. Management's substantial increase in holdings and the company's share repurchase actions consistently and clearly reflect strong confidence in the company's fundamentals and long-term growth prospects.